Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

SOMERSET, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached 316. In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the ONCONASE New Drug Application (NDA). Enrollment in the ONCONASE Phase IIIb clinical trial is scheduled to close on Sept. 30, 2007. To date, a total of 425 patients have been enrolled in the trial.

To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug. Alfacell projects that 316 evaluable events will occur before the end of 2007. Upon reaching this milestone, the company expects to proceed using the following schedule to provide updates regarding the potential completion of the final sections of its ONCONASE rolling NDA submission:

-- Report occurrence of 316 evaluable events via news release within 72

hours of confirmation by Alfacell

-- If data are positive, submit final clinical section of rolling NDA

within four months of reporting 316 evaluable events and announce

submission via news release

Alfacell estimates that it has sufficient cash resources available to continue to fund the completion of the ONCONASE Phase III program and the rolling NDA submission.

In additi
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015  Results from an interim analysis of ... 5g of idarucizumab enabled emergency surgery to be ... with dabigatran (Pradaxa ® dabigatran etexilate mesylate). The ... of dabigatran enabled patients to be urgently brought ... 1.7 hours between administration of idarucizumab and start ...
(Date:9/1/2015)... Sept. 1, 2015 Sargas Pharmaceutical Adherence ... and Drug Adherence m Health applications along with ... process of non face-to-face monitoring of twenty minutes ... release of our apps, doctors are now well ... with our ONCHIT certified Physician, Pharmacy and Patient ...
(Date:9/1/2015)... 2015 The global ... of sectors, products & services and application. And the ... the increasing demand of advanced drugs for the ... the growth for bioinformatics market. The implementation of ... known as bioinformatics. Decreasing cost of DNA sequencing, ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4
... NORTHBROOK, Ill. , May 26 ... on the development and commercialization of innovative medicines ... its New Drug Application (NDA) for DUEXA®, a ... ibuprofen and high-dose famotidine, was accepted by the ...
... , , , ... The U.S. Food and Drug Administration announced today that it will collaborate with the Web ... , , ... Drugs.com seeks to provide patients ...
Cached Medicine Technology:Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing 2Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing 3Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing 4FDA Announces Collaboration With Drugs.com 2
(Date:9/1/2015)... WA (PRWEB) , ... September 01, 2015 , ... Philanthropic ... increasing awareness of societal issues and needs. Money for Good 2015, released today by ... solving it. There’s an annual potential to mobilize up to $22B in new philanthropic ...
(Date:9/1/2015)... ... September 01, 2015 , ... As part of its ... Shield of Minnesota (Blue Cross) has announced Doctor On Demand as the company’s ... Doctor On Demand provides immediate access to Board Certified physicians or next-day appointments ...
(Date:9/1/2015)... ... September 01, 2015 , ... OncLive® today announced ... News & World Report, to provide breaking news and information about the hospital’s ... within OncLive, which provides oncologists resources and information?they need to deliver the best ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, ... entities, announced today that it has hired Scott Sanderson, an experienced business development ... capacity, Sanderson will be responsible for establishing and managing new client relationships in ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... ... care optometric practice, is pleased to announce Dr. Emily S. Kachinsky as the newest ... eye care professionals, headed by Dr. Ronald M. Cline. Dr. Cline, owner of Randolph ... the South Shore and Greater Boston area. , ...
... , TUESDAY, June 29 (HealthDay News) -- American teenage girls ... in years past, a new report says. Girls appear more ... them emotionally, according to a survey by the nonprofit Partnership for ... high school students found 53 percent of girls agreeing with the ...
... sugar level sensor to an insulin pump helps patients with ... the common standard of care, multiple daily insulin injections, concludes ... Journal of Medicine . The paper is ... "Combining the best technologies for insulin delivery and ...
... ... Ready for Distribution to Natural Food Stores and Mainstream Supermarkets Coast-to-Coast. Made from a ... ... LLC, the parent company of MimicCreme®, announced today the release of its truly dairy-free, ...
... patient in four in Germany is in favor of ... in other nations are more satisfied. A working group ... and Efficiency in Health Care (Institut fr Qualitt und ... surveys carried out by the Commonwealth Fund in 2005 ...
... that getting older means losing a mental edge, leading to ... University shows that when it comes to making intuitive decisions ... well as their juniors. The researchers tested groups of ... meaning they live in the community, rather than in ...
Cached Medicine News:Health News:Randolph Eye Associates Continues Growth With the Addition of Dr. Emily S. Kachinsky , 2Health News:Randolph Eye Associates Continues Growth With the Addition of Dr. Emily S. Kachinsky , 3Health News:Teen Girls Becoming More Open to Drugs, Alcohol 2Health News:Teen Girls Becoming More Open to Drugs, Alcohol 3Health News:Sensor and insulin pump results in better blood-sugar control in all age groups with diabetes 2Health News:MimicCreme Announces the Release of its Dairy-Free Whipping Cream - HealthyTop and Two New Flavored Coffee Creamers. 2Health News:Study shows age doesn't necessarily affect decision-making 2
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Anti Gliadin IgG Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... Urinalysis WorkCell System - A Single ... per hour, with true load-and-go productivity ... Clinitek Atlas and UF-100 for complete ... systems working together deliver utmost reliability. ...
... is one of the 3 major naturally ... estrone). In terms of estrogenic activity, estriol ... Estriol is produced almost exclusively during pregnancy, ... the normal human fetus. During pregnancy, the ...
Medicine Products: